160 related articles for article (PubMed ID: 33778924)
1. Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Giziński J; Sajdek M; Wróblewski T; Zieniewicz K; Nyckowski P; Rowiński O
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3673-3683. PubMed ID: 33778924
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
3. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
5. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
8. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38605217
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
[TBL] [Abstract][Full Text] [Related]
11. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
[TBL] [Abstract][Full Text] [Related]
13. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
[TBL] [Abstract][Full Text] [Related]
16. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
17. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.
Zhang Y; Wang J; Li H; Zheng T; Jiang H; Li M; Song B
Ann Transl Med; 2020 Mar; 8(6):388. PubMed ID: 32355832
[TBL] [Abstract][Full Text] [Related]
18. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
